KVUE Kenvue Inc.
Company Analysis
Latest News
Kenvue Completes Debt Exchange Offer with Kimberly-Clark, Modifies Note Covenants
On November 4, 2026, Kimberly-Clark Corporation completed its previously announced exchange offer for various series of Kenvue's outstanding senior notes. A...
Kimberly-Clark Completes Acquisition of Kenvue in Cash and Stock Transaction
Kimberly-Clark Corporation has completed its acquisition of Kenvue, which is now a wholly-owned subsidiary of Kimberly-Clark. As a result of the merger's...
Kenvue Delists as Kimberly-Clark Completes $40 Billion Acquisition
Kenvue Inc. (KVUE) was delisted from the New York Stock Exchange on October 30, 2026, completing its acquisition by Kimberly-Clark Corp. (KMB). The deal is...
Kenvue's third quarter 2026 EPS beat estimates despite soft Skin Health organic sales
Kenvue Inc. reported third quarter 2026 results that exceeded earnings expectations but slightly missed revenue estimates, primarily due to weakness in the...
Kenvue Inc. Q3 2026 Earnings Preview: What Analysts Expect on October 30, 2026
Kenvue Inc. is expected to report Q3 2026 revenue of $3.93 billion and EPS of $0.28, with the current stock price of $25.12 trading below the average analyst...
Kimberly-Clark Wins China’s Approval for $40B Kenvue Acquisition
Kimberly-Clark’s proposed $40 billion acquisition of Kenvue has received antitrust approval from China’s State Administration for Market Regulation, marking a...
Kenvue Loses Bid to Reconsider Ruling Reviving 500 Tylenol Lawsuits
A U.S. appeals court on October 16 denied Kenvue’s request to reconsider a July ruling that revived about 500 lawsuits. [1, 2, 3] The cases allege prenatal...
🟢 Kenvue is trading 4.05% up on October 15, 2026, amid a defensive consumer-staples rotation
Kenvue is trading at $18.74, up 4.05%, as consumer staples advanced amid inflation concerns. - Consumer staples rose 1.90% in regular trading, supporting a...
Kimberly-Clark Secures Conditional EU Approval for $40 Billion Kenvue Deal
The European Commission has granted conditional antitrust approval for Kimberly-Clark’s $40 billion acquisition of Kenvue, the maker of Tylenol and other...
Kenvue Enters Agreement to Amend Debt Covenants Ahead of Kimberly-Clark Acquisition
Kenvue Inc. entered into a Third Supplemental Indenture on October 9, 2026, to amend the terms of its outstanding series of senior notes. This action is being...
Kimberly-Clark Taps Kenvue Leaders as COO Russ Torres Exits
Kimberly-Clark announced leadership changes that will take effect after its pending acquisition of Kenvue, which is expected to close in the fourth quarter of...
Kimberly-Clark offers EU concessions to seal $40 billion Kenvue merger
Kimberly-Clark submitted formal concessions to the European Union to address antitrust concerns regarding its $40 billion acquisition of Kenvue. The European...
Kimberly-Clark Reportedly Planning Asset Sales to Secure EU Approval for Kenvue Deal
Kimberly-Clark is reportedly preparing to offer concessions, including potential asset sales, to address European Union antitrust concerns regarding its...
Kimberly-Clark’s $49B Kenvue Deal Clears Australia, Pending Brand Divestitures
The Australian Competition and Consumer Commission (ACCC) granted conditional approval for Kimberly-Clark’s acquisition of Kenvue on September 2, 2026. To...
Kimberly-Clark Seeks EU Approval for $40B Kenvue Deal, Targeting Health Market
Kimberly-Clark formally requested antitrust approval from the European Commission for its $40 billion acquisition of Kenvue. The target company manufactures...
Kimberly-Clark’s $49B Kenvue Deal Faces Deeper China Probe, Expert Urges Slowdown
China’s State Administration for Market Regulation (SAMR) escalated its review of Kimberly-Clark’s $49 billion acquisition of Kenvue. The regulator moved the...
Kenvue's second quarter revenue of $3.96 billion misses estimates, though organic sales grew 1.6%.
Kenvue reported second quarter 2026 net sales of $3.96 billion, up 3.0% year-over-year, and adjusted diluted EPS of $0.31, a 7% increase. The results narrowly...
Kenvue Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Wall Street analysts project Kenvue to report Q2 2026 revenue of $3.97 billion and adjusted EPS of $0.32, with the current stock price of $19.24 sitting just...
J&J proposes $5.5B talc settlement, easing Kenvue liability
Johnson & Johnson proposed a $5.5 billion settlement to resolve approximately 76,000 U.S. lawsuits alleging its talc-based baby powder caused ovarian cancer....
Kenvue Secures FDA Approval for First Tylenol and Naproxen Combination Pill
The U.S. Food and Drug Administration (FDA) approved Kenvue’s new over-the-counter (OTC) medication, Tylenol with Naproxen. This product is the first to...